Trial in children could help increase vaccine coverage

26 March 2021
biontech_vaccine_large

Adding to existing trials in older children, Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) have initiated a study of their coronavirus vaccine in children aged 6-12.

With the first children being dosed in the USA, results from the study should be available by the latter part of 2020, with regulatory approval and rollout at the start of next year.

Moderna (Nasdaq: MRNA) has also begun testing its vaccine in children over 12.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology